As the use of AI spreads through every industry and becomes more of a part of our lives every day, researchers are also ...
Life just got more difficult for those fighting antibiotic-resistant superbugs. Researchers at McGill University have ...
That problem is why, even though we’ve had success finding enzymes that break down common plastics like polyesters and PET, they’re only partial solutions to plastic waste. However, researchers aren’t ...
An international study has uncovered a new vulnerability in prostate cancer cells that could help improve treatment for one of the most common cancers affecting men. The research, published in the ...
The manuscript concerns a fundamental and controversial question in Trypanosoma brucei biology and the parasite life cycle, providing further evidence that slender bloodstream forms can indeed infect ...
Tvardi Therapeutics has failed its first big test as a public company. Months after joining the Nasdaq, the biotech has reported the unappetizing mix of high dropout rates and placebolike efficacy in ...
State Key Laboratory for Quality and Safety of Agro-Products, Key Laboratory of Biotechnology in Plant Protection of MARA, Zhejiang Key Laboratory of Green Plant Protection, Institute of Plant ...
After Omeros decided to hit pause on developing its MASP-3 inhibitor zaltenibart, Novo Nordisk has spied an opportunity to scoop up the rare disease drug. Omeros spent the first weeks of the year ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological ...
Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare Disease portfolio Omeros is eligible to receive 340 million US dollars in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback